Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
Trial ID or NCT#
NCT00068419
Status
NOT RECRUITING
Purpose
This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more cancer cells.
Official Title
A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy
Eligibility Criteria
Ages Eligible for Study: Younger than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Peds Hem/Onc CRAs
650-723-5535
View on ClinicalTrials.gov
